The Day Greggs Blinked

When sausage roll profits meet appetite-suppressing drugs, the truth about cravings writes itself

The boss of Greggs just admitted something rather telling.

Roisin Currie, the company’s CEO, said there was “no doubt” that appetite-suppressing drugs like Ozempic and Wegovy have led customers to want “smaller portions.” People are asking for more protein and fibre. They want healthier options. And it’s hitting the company’s bottom line.

Let that sink in for a moment.

The biggest fast food chains in Britain, a company built on sausage rolls, steak bakes and doughnuts, is watching its customers walk away. Not because of a new diet trend. Not because of a government campaign. Because a drug that fixes a hormone is doing what decades of “eat less, move more” advice never could.

That’s the bit nobody’s talking about.

These drugs work by mimicking a hormone called GLP-1, which tells your brain you’re full. When the hormone works properly, you stop wanting the rubbish. You don’t crave the sausage roll at 11am. You don’t need the doughnut after lunch. The desire just fades.

But here’s what I find fascinating. Your body already makes GLP-1. You don’t need a £200-a-month injection to switch it on. Eating real food, particularly protein and fibre (the exact things

Greggs customers are now demanding), triggers the same hormone naturally. It’s slower, yes. But it’s free, it’s sustainable, and it doesn’t come with the side effects.

The real lesson from this Greggs story isn’t about sausage rolls or share prices. It’s proof that when you sort out the hormones, the cravings take care of themselves. It was never about willpower. It was always about biology.

Greggs knows it. Their shareholders know it. Now you know it too.

Your action today: Before your next meal, eat a handful of protein or a portion of vegetables first. You’ll trigger your own GLP-1 and feel fuller faster, no injection required.